Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 2, 2008, Pages 267-272

  Goto, Shuji ^a   Seo, Takayuki ^a   Hagiwara, Takashi ^a   Ueda, Kentaro ^a   Yamauchi, Tsuyuko ^b   Nagata, Shiro ^b   Ando, Yukio ^b,c   Ishitsu, Takateru ^d   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Kumamoto Saishunsou National Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CARNITINE; GAMMA GLUTAMYLTRANSFERASE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; ENZYME DEFECT; EPILEPSY; FEMALE; HUMAN; JAPANESE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

ADOLESCENT; ADULT; AMMONIA; ANTICONVULSANTS; BODY WEIGHT; CARNITINE; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; INFANT; JAPAN; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS; TRANSAMINASES; VALPROIC ACID;

EID: 38949157116     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.2.0017     Document Type: Article

References (32)

1. Amacher, D. E. (1998) Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul. Toxicol. Pharmacol. 27: 119-130
2. Atmaca, A., Al-Batran, S. E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hovelmann, S., Gottlicher, M., Knuth, A., Jager, E. (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer 97: 177-182
3. Bohan, T. P., Helton, E., McDonald, I., König, S., Gazit, T. S., Sugimoto, T., Scheffner, D., Cusmano, L., Li, S., Koch, G.. (2001) Effect of L-carnitine treatment for valptoate-induced hepatotoxicity. Neurology 56: 1405-1409
4. Bryant, A. E. 3rd., Dreifuss, F. E. (1986) Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46: 465-469
5. Burgert, T. S., Taksali, S.E., Dziura, J., Goodman, T. R., Yeckel, C. W., Papademetris, X., Constable, R. T., Weiss, R., Tamborlane, W. V., Savoye, M., Seyal, A. A., Caprio, S. (2006) Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J. Clin. Endocrinol. Metab. 91: 4287-4294
6. Chang, T. K., Abbott, F. S. (2006) Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab. Rev. 38: 627-639
7. Coppola, G., Epifanio, G., Auricchio, G., Federico, R. R., Resicato, G., Pascotto, A. (2006) Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev. 28: 358-365
8. Denicoff, K. D., Smith-Jackson, E. E., Bryan, A. L., Ali, S. O. Post, R. M. (1997) Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am. J. Psychiatry 154: 1456-1458
9. De Vivo, D. C., Bohan, T. P., Coulter, D. L., Dreifuss, F. E., Greenwood, R. S., Nordli, D. R. Jr., Shields, W. D., Stafstrom, C. E., Tein, I. (1998) L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39: 1216-1225
10. Emdin, M., Pompella, A., Paolicchi, A. (2005) Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 112: 2078-2080
11. Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., Ceconi, C. (2004) Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann. N. Y. Acad. Sci. 1033: 79-91
12. Foster, D. W. (2004) The role of the carnitine system in human metabolism. Ann. N. Y. Acad. Sci. 1033: 1-16
13. Gerstner, T., Woelfing, C., Witsch, M., Longin, E., Bell, N., Konig, S. (2006) Capillary microscopy and hemorheology in children during antiepileptic monotherapy with carbamazepine and valproate. Seizure 15: 606-609
14. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4: 489-499
15. Koenig, S. A., Buesing, D., Longin, E., Oehring, R., Haussermann, P., Kluger, G., Lindmayer, F., Hanusch, R., Degen, I., Kuhn, H., Samii, K., Jungck, A., Bruckner, R., Seitz, R., Boxtermann, W., Weber, Y., Knapp, R., Richard, H. H., Weidner, B., Kasper, J. M., Haensch, C. A., Fitzek, S., Hartmann, M., Borusiak, P., Muller-Deile, A., Degenhardt, V., Korenke, G. C., Hoppen, T., Specht, U., Gerstner, T. (2006) Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47: 2027-2031
16. Kondo, T., Kaneko, S., Otani, K., Ishida, M., Hirano, T., Fukushima, Y., Muranaka, H., Koide, N., Yokoyama, M. (1992) Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 33: 172-177
17. Kreher, U., Darius, J., Wien, F. (2002) Abnormal alterations in the metabolic patterns of patients on valproate therapy. J. Pharm. Pharmacol. 54: 989-995
18. Lee, D. H., Silventoinen, K., Hu, G., Jacobs, D. R. Jr., Jousilahti, P., Sundvall, J., Tuomilehto, J. (2006) Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur. Heart J. 27: 2170-2176
19. Levy, R. H., Rettenmeier, A. W., Anderson, G. D., Wilensky, A. J., Friel, P. N., Baillie, T. A., Acheampong, A., Tor, J., Guyot, M., Loiseau, P. (1990) Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. 48: 225-235
20. Lheureux, P. E., Penaloza, A., Zahir, S., Gris, M. (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit. Care 9: 431-440
21. LoVecchio, F., Shriki, J., Samaddar, R. (2005) L-carnitine was safely administered in the setting of valproate toxicity. Am. J. Emerg. Med. 23: 321-322
22. Luef, G. J., Waldmann, M., Sturm, W., Naser, A., Trinka, E., Unterberger, I., Bauer, G., Lechleitner, M. (2004) Valproate therapy and nonalcoholic fatty liver disease. Ann. Neurol. 55: 729-732
23. Peterson, G. M., Naunton, M. (2005) Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30: 417-421
24. Perucca, E. (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16: 695-714
25. Pylvänen, V., Pakarinen, A., Knip, M., Isojärvi, J. (2006) Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 47: 1460-1464
26. Raskind, J. Y., EL-Chaar, GM. (2000) The role of carnitine supplementation during valproic acid therapy. Ann. Pharmacother. 34: 630-638
27. Ruttmann, E., Brant, L. J., Concin, H., Diem, G., Rapp, K., Ulmer, H., Vorarlberg Health Monitoring and Promotion Program Study Group. (2005) Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112: 2130-2137
28. Serrano, B. B., Garcia Sanchez, M. J., Otero, M. J., Buelga, D. S., Serrano, J., Dominguez-Gil, A. (1999) Valproate population pharmacokinetics in children. J. Clin. Pharm. Ther. 24: 73-80
29. Takahashi, M., Ueda, S., Misaki, H., Sugiyama, N., Matsumoto, K., Matsuno, N., Murao, S. (1994) Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin. Chem. 40: 817-821
30. Wall, M., Baird-Lambert, J., Buchanan, N., Farrell, G. (1992) Liver function tests in persons receiving anticonvulsant medications. Seizure 1: 187-190
31. Watkins, P. B., Seeff, L. B. (2006) Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43: 618-631
32. Yukawa, E., Nonaka, T., Yukawa, M., Higuchi, S., Kuroda, T., Goto, Y. (2003) Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J. Clin. Pharm. Ther. 28: 497-504